HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Diosmin, a citrus fruit-derived phlebotonic bioflavonoid protects rats from chronic kidney disease-induced loss of bone mass and strength without deteriorating the renal function.

Abstract
Kidney Disease Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline has recommended treatment decisions for patients with chronic kidney disease (CKD) with osteoporosis and/or high risk of fracture. Bisphosphonates, the first-line anti-osteoporosis drugs have the concern of worsening kidney functions. Moreover, despite impaired bone formation in CKD patients, teriparatide, the formation-stimulating drug is not recommended. Thus, there is an urgent need for safe and effective treatment of osteoporosis in CKD patients. Here, in CKD rats, we tested the osteoprotective effect of diosmin, a citrus-derived bioflavonoid used as a phlebotonic in chronic venous insufficiency and has a renoprotective effect. CKD was developed by 5/6th nephrectomy and diosmin at the human equivalent dose (100 mg kg-1) did not advance renal failure but reduced blood pressure to the level of sham control. Fibroblast growth factor-23 and parathyroid hormone were increased in CKD and diosmin suppressed both. CKD reduced bone mass and deteriorated the microarchitecture of trabecular bones, and diosmin maintained both to control levels. Bone formation and strength were impaired in the CKD and diosmin maintained these levels to control levels. Nanoindentation of bone showed that diosmin significantly increased tissue hardness over the control. Diosmetin, the metabolic surrogate of diosmin had comparable pharmacokinetic profiles between the control and CKD groups. Furthermore, diosmetin (50 mg kg-1) protected against CKD-induced bone loss. These data suggest that diosmin and its metabolic surrogate, diosmetin protect against CKD-induced osteopenia. Since diosmin has no renal adverse effect and protected bone mass and strength in CKD rats, we propose assessing its anti-osteoporosis effect in CKD patients.
AuthorsShivani Sharma, Konica Porwal, Chirag Kulkarni, Subhashis Pal, Praveer Sihota, Saroj Kumar, Mahesh Chandra Tiwari, Roshan Katekar, Ashish Kumar, Priya Singh, Swati Rajput, Rajdeep Guha, Navin Kumar, Jiaur R Gayen, Naibedya Chattopadhyay
JournalFood & function (Food Funct) Vol. 13 Issue 4 Pg. 2184-2199 (Feb 21 2022) ISSN: 2042-650X [Electronic] England
PMID35119062 (Publication Type: Journal Article)
Chemical References
  • Flavonoids
  • Protective Agents
  • Diosmin
Topics
  • Animals
  • Bone Density (drug effects)
  • Cancellous Bone (drug effects)
  • Citrus
  • Diosmin (pharmacology, therapeutic use)
  • Disease Models, Animal
  • Female
  • Flavonoids (pharmacology, therapeutic use)
  • Osteoporosis (complications, prevention & control)
  • Phytotherapy
  • Protective Agents (pharmacology, therapeutic use)
  • Rats
  • Renal Insufficiency, Chronic (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: